Ionis to hold donidalorsen Phase 3 data webcast

Core Insights - Ionis Pharmaceuticals will host a live webcast on May 31, 2024, at 8:00 a.m. Eastern Time to discuss the results of the donidalorsen Phase 3 OASIS-HAE and OASISplus studies [1] - The study results will be presented in three late-breaking oral presentations at the 2024 European Academy of Allergy and Clinical Immunology Annual Meeting in Valencia, Spain [1] Company Overview - Ionis Pharmaceuticals has been innovating medicines for over three decades, focusing on serious diseases [3] - The company currently markets five medicines and has a strong pipeline in neurology, cardiology, and other high-need areas [3] - As a pioneer in RNA-targeted medicines, Ionis is advancing RNA therapies and exploring new gene editing approaches [3]